Gestational diabetes & diabetes in pregnancy
Association of Acylcarnitines With Maternal Cardiometabolic Risk Factors Is Defined by Chain Length: The S-PRESTO Study
Authors' conclusion
This study provides the metabolic and physiological basis of maternal carnitine homeostasis, which can be used in assessment of maternal cardiometabolic health at preconception to improve pregnancy outcomes.
Study context
- Population
- Mothers in the S-PRESTO cohort; plasma and urine sampled at preconception, 26–28 weeks' pregnancy and 3 months postpartum765 plasma, 702 urine samples
- Outcome
- Association of maternal plasma and urinary free carnitine and acylcarnitines with cardiometabolic risk factors
Main finding
As reported in the abstract
Mothers who developed GDM had higher plasma propionylcarnitine at preconception vs normal glucose metabolism
∼10%
Mothers who developed GDM had higher urine tiglylcarnitine at preconception vs normal glucose metabolism
∼18%
Observational data: associations, not effects.
Original publication
Association of Acylcarnitines With Maternal Cardiometabolic Risk Factors Is Defined by Chain Length: The S-PRESTO Study. J Clin Endocrinol Metab. Published 16 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →